Sakar Healthcare LimitedQ1FY27 Results & Financial Update
Sakar Healthcare Limited: Q1FY27 consolidated results and company financials – revenue ₹72.97 Cr, PAT ₹10.28 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Sakar Healthcare price & chart
Market price₹1,075.00
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Sakar Healthcare Q1FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Sakar Healthcare registered a robust start to fiscal 2027, reporting consolidated revenue from operations of INR 72.97 crore for the quarter ended June 30, 2026, supported by expanding oncology product authorizations and broad-based export demand.
Profitability expanded significantly during the quarter, with profit after tax reaching INR 10.28 crore and basic earnings per share standing at INR 4.62, driven by operating leverage, enhanced production efficiencies, and improved gross margins.
The company's gross profit for the quarter stood at INR 38.39 crore, representing a gross profit margin of 53%, compared with 45% in the corresponding period of the previous year.
Operating performance benefited from disciplined cost management alongside higher contributions from high-margin oncology products, which deliver approximately double the margins of general formulations.
Total income for Q1 FY27 was recorded at INR 74.52 crore, which included other income of INR 1.54 crore, while total expenses aggregated to INR 59.94 crore.
Finance costs for the quarter were contained at INR 1.67 crore and depreciation and amortization expenses stood at INR 6.54 crore.
The company maintains an active strategy of scaling its oncology portfolio through international marketing authorizations, dossier submissions, and technology transfer arrangements with global pharmaceutical leaders.
01 · Business model
What does Sakar Healthcare do?
Sakar Healthcare Limited is an Ahmedabad-headquartered pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations.
The company operates WHO-GMP and EU-GMP certified manufacturing facilities in Gujarat, covering oral solids, injectables, oral liquids, and high-potent oncology products.
Sakar's oncology facility at Bavla is a research-driven, API-integrated unit featuring capabilities from active pharmaceutical ingredients to finished dosage forms, supporting complex cytotoxic formulations.
The business serves customers globally across more than 60 countries through contract development and manufacturing (CDMO/CMO), own brand exports, and technology transfer partnerships with multinational pharmaceutical companies.
02 · Historical context
What shaped the business before this quarter
Founded by Mr. Sanjay Shah, Sakar Healthcare has evolved over two decades from a traditional contract manufacturer into an API-integrated pharmaceutical organization with a specialized focus on oncology formulations.
The company previously established a state-of-the-art oncology facility at Bavla in Gujarat, equipped with integrated API and finished dosage formulation capabilities to shift towards value-driven vertical integration.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1FY27 |
|---|---|
| Revenue from operations | ₹72.97 Cr |
| Total income | ₹74.52 Cr |
| Profit before tax | ₹14.58 Cr |
| Profit after tax | ₹10.28 Cr |
| EPS | ₹4.62 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 14.1% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 20.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹1.54 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Growth was strongly supported by new market authorizations and strong international demand for oncology products across regulated and emerging markets.
The company executed more than 65 oncology product contracts during the quarter, with over 50 additional commercial discussions underway.
What drove margins
The increasing share of high-margin oncology formulations, which deliver approximately two times higher margins compared to general formulations, helped improve profitability.
Higher capacity utilization and operational efficiencies across manufacturing units contributed to gross profit margin expansion to 53% from 45% year-on-year.
05 · Demand, customers & order book
Where demand is coming from
Sakar shared 261 dossiers globally during the quarter, of which 178 were submitted and 16 received marketing authorizations. Dossiers for 21 of the 32 developed oncology products secured 16 dossier approvals.
The company maintains active relationships with 15 supply partners and 19 API supply partners supporting 8 products.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single primary business segment dedicated to the manufacturing of pharmaceutical products, including liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables, and lyophilized injections.
Geography and market mix
Sakar maintains an active commercial presence across more than 60 countries, spanning Europe, the UK, MENA, Africa, Latin America, Canada, APAC, and CIS regions.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company has developed 21 APIs in-house, including 16 APIs with written confirmation, 8 commercialized products, 2 APIs with CEP approval, and 5 CEP applications currently in process.
Operations utilize advanced containment systems up to OEL Level 4, automated lines sourced from global machinery makers such as GEA, Glatt, and Tofflon, and green chemistry principles including zero liquid discharge systems.
Projects, capex and execution
33 technology transfer projects for oncology products are underway with major partners including Accord-Intas, Torrent, Emcure, Glenmark, and Zydus, with 7 projects having received site variation approvals.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The recent partnership with Zydus Lifesciences for GCC and other emerging markets marked Sakar's 40th global anti-cancer product agreement.
09 · Reported developments
What changed operationally
Completed 26 EU marketing authorization filings, including 15 owned filings, and submitted 33 site variations covering 18 cytotoxic molecules across the EU and the UK, of which 7 have been approved.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The company reported zero financial indebtedness, with no outstanding defaults on loans, revolving credit facilities, or debt securities.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Secretarial and cost auditor appointments
The Board of Directors approved the appointment of M/s. Kashyap R. Mehta & Partners as secretarial auditors for a five-year term from FY 2026-27 to FY 2030-31 and M/s. Dalwadi & Associates as cost auditors for FY 2026-27.
12 · Key Q&A
The quarter, answered directly
What does Sakar Healthcare do?
Sakar Healthcare Limited is an Ahmedabad-headquartered pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations.
What is the clearest takeaway from Q1FY27?
Sakar Healthcare registered a robust start to fiscal 2027, reporting consolidated revenue from operations of INR 72.97 crore for the quarter ended June 30, 2026, supported by expanding oncology product authorizations and broad-based export demand.
What drove revenue or demand?
Growth was strongly supported by new market authorizations and strong international demand for oncology products across regulated and emerging markets.
What mattered most for margins or profitability?
The increasing share of high-margin oncology formulations, which deliver approximately two times higher margins compared to general formulations, helped improve profitability.
What changed operationally beyond the headline numbers?
The company has developed 21 APIs in-house, including 16 APIs with written confirmation, 8 commercialized products, 2 APIs with CEP approval, and 5 CEP applications currently in process.
What should the next disclosure help confirm?
Monitor the commercial launch and supply ramp-up following recent EU and UK marketing authorizations and site variation approvals for oncology products.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Conversion of regulatory approvals: Monitor the commercial launch and supply ramp-up following recent EU and UK marketing authorizations and site variation approvals for oncology products.
- 02
Technology transfer execution: Track the progress of the 33 ongoing oncology technology transfer projects with global pharmaceutical partners towards final site approvals and commercialization.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.